Abstract
Aliphatic and aromatic ferrocenylthiosemicarbazones were synthesized. The characterization of the new ferrocenylthiosemicarbazones was done by IR, 1H-NMR and 13C-NMR spectroscopy, elemental analysis and X-ray diffraction studies. The biological activity of the obtained compounds was assessed in terms of anticancer activity. Their activity against U251 (human glyoblastoma), PC-3 (human prostatic adenocarcinoma), K562 (human chronic myelogenous leukemia), HCT-15 (human colorectal adenocarcinoma), MCF-7 (human mammary adenocarcinoma) and SKLU-1 (human lung adenocarcinoma) cell lines was studied and compared with cisplatin. All tested compounds showed good activity and the aryl-chloro substituted ferrocenylthiosemicarbazones showed the best anticancer activity.
Keywords: Anti-cancer activity, ferrocene, thiosemicarbazones.
Anti-Cancer Agents in Medicinal Chemistry
Title:Anticancer Activity of Ferrocenylthiosemicarbazones
Volume: 14 Issue: 3
Author(s): Cortez-Maya Sandra, Klimova Elena, Flores-Alamo Marcos, Martínez-Klimova Elena, Ramírez-Ramírez Arturo, Ramírez Apan Teresa and Martínez-García Marcos
Affiliation:
Keywords: Anti-cancer activity, ferrocene, thiosemicarbazones.
Abstract: Aliphatic and aromatic ferrocenylthiosemicarbazones were synthesized. The characterization of the new ferrocenylthiosemicarbazones was done by IR, 1H-NMR and 13C-NMR spectroscopy, elemental analysis and X-ray diffraction studies. The biological activity of the obtained compounds was assessed in terms of anticancer activity. Their activity against U251 (human glyoblastoma), PC-3 (human prostatic adenocarcinoma), K562 (human chronic myelogenous leukemia), HCT-15 (human colorectal adenocarcinoma), MCF-7 (human mammary adenocarcinoma) and SKLU-1 (human lung adenocarcinoma) cell lines was studied and compared with cisplatin. All tested compounds showed good activity and the aryl-chloro substituted ferrocenylthiosemicarbazones showed the best anticancer activity.
Export Options
About this article
Cite this article as:
Sandra Cortez-Maya, Elena Klimova, Marcos Flores-Alamo, Elena Martínez-Klimova, Arturo Ramírez-Ramírez, Teresa Apan Ramírez and Marcos Martínez-García, Anticancer Activity of Ferrocenylthiosemicarbazones, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (3) . https://dx.doi.org/10.2174/18715206113136660365
DOI https://dx.doi.org/10.2174/18715206113136660365 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Circulating Tumor Cells: A New Window for Diagnosis and Evaluation of Cancer
Anti-Cancer Agents in Medicinal Chemistry Silimarin and Cancer
Anti-Cancer Agents in Medicinal Chemistry Novel Drug Therapies for Fertility Preservation in Men Undergoing Chemotherapy: Clinical Relevance of Protector Agents
Current Medicinal Chemistry Advances and Barriers in Mammalian Cell Encapsulation for Treatment of Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer
Current Pharmaceutical Design Signaling Pathways Responsible for Cancer Cell Invasion as Targets for Cancer Therapy
Current Cancer Drug Targets Targeted Therapies for Prostate Cancer Against the Prostate Specific Membrane Antigen
Current Drug Targets Neuroendocrine Tumors of the Lung: Hystological Classification, Diagnosis, Traditional and New Therapeutic Approaches
Current Medicinal Chemistry Curcumin: Powerful Immunomodulator from Turmeric
Current Immunology Reviews (Discontinued) Animal Modeling of Cancer Pathology and Studying Tumor Response to Therapy
Current Drug Targets Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Demystifying the ACE Polymorphism: From Genetics to Biology
Current Pharmaceutical Design Small-Animal Molecular Imaging for Preclinical Cancer Research: μPET and μSPECT
Current Radiopharmaceuticals Current Biomarkers for Lung Cancer
Current Signal Transduction Therapy Prospects for Plant-Derived Chemopreventive Agents Exhibiting Multiple Mechanisms of Action
Current Medicinal Chemistry - Anti-Cancer Agents Therapeutic Targeting of Cancers with Loss of PTEN Function
Current Drug Targets Pharmacogenomics Opportunities in Nuclear Receptor Targeted Cancer Therapy
Current Cancer Drug Targets Epothilones: From Discovery to Clinical Trials
Current Topics in Medicinal Chemistry Purine Ionotropic (P2X) Receptors
Current Pharmaceutical Design Hypothalamic Glucose Sensing and Glycaemic Disease
Current Diabetes Reviews